194 related articles for article (PubMed ID: 27199259)
1. Functional reprogramming of human prostate cancer to promote local attraction of effector CD8(+) T cells.
Muthuswamy R; Corman JM; Dahl K; Chatta GS; Kalinski P
Prostate; 2016 Sep; 76(12):1095-105. PubMed ID: 27199259
[TBL] [Abstract][Full Text] [Related]
2. Combination of IFNα and poly-I:C reprograms bladder cancer microenvironment for enhanced CTL attraction.
Muthuswamy R; Wang L; Pitteroff J; Gingrich JR; Kalinski P
J Immunother Cancer; 2015; 3():6. PubMed ID: 25806105
[TBL] [Abstract][Full Text] [Related]
3. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
[TBL] [Abstract][Full Text] [Related]
4. NF-κB hyperactivation in tumor tissues allows tumor-selective reprogramming of the chemokine microenvironment to enhance the recruitment of cytolytic T effector cells.
Muthuswamy R; Berk E; Junecko BF; Zeh HJ; Zureikat AH; Normolle D; Luong TM; Reinhart TA; Bartlett DL; Kalinski P
Cancer Res; 2012 Aug; 72(15):3735-43. PubMed ID: 22593190
[TBL] [Abstract][Full Text] [Related]
5. Systemic infusion of TLR3-ligand and IFN-α in patients with breast cancer reprograms local tumor microenvironments for selective CTL influx.
Gandhi S; Opyrchal M; Grimm MJ; Slomba RT; Kokolus KM; Witkiewicz A; Attwood K; Groman A; Williams L; Tarquini ML; Wallace PK; Soh KT; Minderman H; Maguire O; O'Connor TL; Early AP; Levine EG; Kalinski P
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37963636
[TBL] [Abstract][Full Text] [Related]
6. COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells.
Fujita M; Kohanbash G; Fellows-Mayle W; Hamilton RL; Komohara Y; Decker SA; Ohlfest JR; Okada H
Cancer Res; 2011 Apr; 71(7):2664-74. PubMed ID: 21324923
[TBL] [Abstract][Full Text] [Related]
7. IL-17 inhibits CXCL9/10-mediated recruitment of CD8
Chen J; Ye X; Pitmon E; Lu M; Wan J; Jellison ER; Adler AJ; Vella AT; Wang K
J Immunother Cancer; 2019 Nov; 7(1):324. PubMed ID: 31775909
[TBL] [Abstract][Full Text] [Related]
8. High-dose per Fraction Radiotherapy Induces Both Antitumor Immunity and Immunosuppressive Responses in Prostate Tumors.
Lin L; Kane N; Kobayashi N; Kono EA; Yamashiro JM; Nickols NG; Reiter RE
Clin Cancer Res; 2021 Mar; 27(5):1505-1515. PubMed ID: 33219015
[TBL] [Abstract][Full Text] [Related]
9. Peritumoural CCL1 and CCL22 expressing cells in hepatocellular carcinomas shape the tumour immune infiltrate.
Wiedemann GM; Röhrle N; Makeschin MC; Fesseler J; Endres S; Mayr D; Anz D
Pathology; 2019 Oct; 51(6):586-592. PubMed ID: 31445808
[TBL] [Abstract][Full Text] [Related]
10. Modulation of CXCR3 ligand secretion by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer.
Bronger H; Kraeft S; Schwarz-Boeger U; Cerny C; Stöckel A; Avril S; Kiechle M; Schmitt M
Breast Cancer Res; 2012 Feb; 14(1):R30. PubMed ID: 22333315
[TBL] [Abstract][Full Text] [Related]
11. NFκB-Activated COX2/PGE
Ibrahim OM; Basse PH; Jiang W; Guru K; Chatta G; Kalinski P
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33809455
[TBL] [Abstract][Full Text] [Related]
12. IFN-alpha2a induces IP-10/CXCL10 and MIG/CXCL9 production in monocyte-derived dendritic cells and enhances their capacity to attract and stimulate CD8+ effector T cells.
Padovan E; Spagnoli GC; Ferrantini M; Heberer M
J Leukoc Biol; 2002 Apr; 71(4):669-76. PubMed ID: 11927654
[TBL] [Abstract][Full Text] [Related]
13. T-cell mediated induction of allogeneic endothelial cell chemokine expression.
Kobayashi H; Koga S; Novick AC; Toma H; Fairchild RL
Transplantation; 2003 Feb; 75(4):529-36. PubMed ID: 12605122
[TBL] [Abstract][Full Text] [Related]
14. Forced LIGHT expression in prostate tumors overcomes Treg mediated immunosuppression and synergizes with a prostate tumor therapeutic vaccine by recruiting effector T lymphocytes.
Yan L; Da Silva DM; Verma B; Gray A; Brand HE; Skeate JG; Porras TB; Kanodia S; Kast WM
Prostate; 2015 Feb; 75(3):280-91. PubMed ID: 25399517
[TBL] [Abstract][Full Text] [Related]
15. Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation.
Muthuswamy R; Urban J; Lee JJ; Reinhart TA; Bartlett D; Kalinski P
Cancer Res; 2008 Jul; 68(14):5972-8. PubMed ID: 18632653
[TBL] [Abstract][Full Text] [Related]
16. Targeted knock down of CCL22 and CCL17 by siRNA during DC differentiation and maturation affects the recruitment of T subsets.
Kang S; Xie J; Ma S; Liao W; Zhang J; Luo R
Immunobiology; 2010; 215(2):153-62. PubMed ID: 19450895
[TBL] [Abstract][Full Text] [Related]
17. TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients.
Hossain DM; Pal SK; Moreira D; Duttagupta P; Zhang Q; Won H; Jones J; D'Apuzzo M; Forman S; Kortylewski M
Clin Cancer Res; 2015 Aug; 21(16):3771-82. PubMed ID: 25967142
[TBL] [Abstract][Full Text] [Related]
18. Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade.
House IG; Savas P; Lai J; Chen AXY; Oliver AJ; Teo ZL; Todd KL; Henderson MA; Giuffrida L; Petley EV; Sek K; Mardiana S; Gide TN; Quek C; Scolyer RA; Long GV; Wilmott JS; Loi S; Darcy PK; Beavis PA
Clin Cancer Res; 2020 Jan; 26(2):487-504. PubMed ID: 31636098
[TBL] [Abstract][Full Text] [Related]
19. Helicase-Driven Activation of NFκB-COX2 Pathway Mediates the Immunosuppressive Component of dsRNA-Driven Inflammation in the Human Tumor Microenvironment.
Theodoraki MN; Yerneni S; Sarkar SN; Orr B; Muthuswamy R; Voyten J; Modugno F; Jiang W; Grimm M; Basse PH; Bartlett DL; Edwards RP; Kalinski P
Cancer Res; 2018 Aug; 78(15):4292-4302. PubMed ID: 29853604
[TBL] [Abstract][Full Text] [Related]
20. Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy.
Jordan JT; Sun W; Hussain SF; DeAngulo G; Prabhu SS; Heimberger AB
Cancer Immunol Immunother; 2008 Jan; 57(1):123-31. PubMed ID: 17522861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]